Controversy

Whether amino-acid PET (FET/FDOPA/MET) should be standard-of-care adjunct for progression/recurrence vs remains access-limited and under-validated

Evidence profile

Status: awaiting_review. Rule: atlas-profile-2.0.

3 linked publications; not a count of independent studies.

Missing appraisal does not mean no evidence exists. Inspect the full profile and source relationships in the interactive Atlas.

Historical grade: WEAK (retained from 22 September 2026; not a completed profile 2.0 assessment).

Position A

PET-RANO/RANO working group and reviews support amino-acid PET for treatment-response and recurrence assessment

Position B

Evidence is largely single-center, heterogeneous thresholds, limited availability; prospective outcome-linked validation sparse

Clinical stakes

Could resolve pseudoprogression problem but access and standardization limit reach

Open in the interactive atlas →

About this page

Curated and maintained by Resonant Labs. Editorial lead: E. Brooke Schrickel, M.D. Claims are synthesized from the cited literature and graded per the Atlas methodology (about the Atlas). Page generated 2026-10-02. This is not a new clinical review date.

This is an educational research resource from Resonant Labs, not clinical advice. Atlas assessments are heuristic, not probabilities or formal GRADE ratings. Findings are summarized from the literature and may change as the field evolves.